When will the FDA approve Intellia Therapeutics' lonvo-z?

Prediction market on kalshi. If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.

Liquidity: $1,220.52. Resolves: 7/8/2027.